%0 Journal Article
%A de Miguel-Perez, Diego
%A Russo, Alessandro
%A Arrieta, Oscar
%A Ak, Murat
%A Barron, Feliciano
%A Gunasekaran, Muthukumar
%A Mamindla, Priyadarshini
%A Lara-Mejia, Luis
%A Peterson, Christine B
%A Er, Mehmet E
%A Peddagangireddy, Vishal
%A Buemi, Francesco
%A Cooper, Brandon
%A Manca, Paolo
%A Lapidus, Rena G
%A Hsia, Ru-Ching
%A Cardona, Andres F
%A Naing, Aung
%A Kaushal, Sunjay
%A Hirsch, Fred R
%A Mack, Philip C
%A Serrano, Maria Jose
%A Adamo, Vincenzo
%A Colen, Rivka R
%A Rolfo, Christian
%T Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer.
%D 2022
%U http://hdl.handle.net/10668/20349
%X Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictive biomarkers. Liquid biopsy is the non-invasive and repeatable analysis of biological material in body fluids and a promising tool for cancer biomarkers discovery. In particular, there is growing evidence that extracellular vesicles (EVs) play an important role in tumor progression and in tumor-immune interactions. Thus, we evaluated whether extracellular vesicle PD-L1 expression could be used as a biomarker for prediction of durable treatment response and survival in patients with non-small cell lung cancer (NSCLC) undergoing treatment with ICIs. Dynamic changes in EV PD-L1 were analyzed in plasma samples collected before and at 9 ± 1 weeks during treatment in a retrospective and a prospective independent cohorts of 33 and 39 patients, respectively. As a result, an increase in EV PD-L1 was observed in non-responders in comparison to responders and was an independent biomarker for shorter progression-free survival and overall survival. To the contrary, tissue PD-L1 expression, the commonly used biomarker, was not predictive neither for durable response nor survival. These findings indicate that EV PD-L1 dynamics could be used to stratify patients with advanced NSCLC who would experience durable benefit from ICIs.
%K Biomarkers
%K Extracellular vesicles
%K Immunotherapy
%K NSCLC
%K PD-L1
%~